Canada: Judge Phelan's Comments For The Pharmaceutical Industry: Apotex Inc. v Canada (Minister Of Health)

In Apotex Inc. v Canada (Minister of Health) ("Apotex"), the Federal Court (the "Court") provided some guidance with respect to the procedure pharmaceutical companies should undertake to obtain a Notice of Compliance ("NOC"). Overall, the Court's findings suggest that pharmaceutical companies should put their best foot forward in their application or on appeal in front of expert panels considering or reconsidering their applications because overturning an expert panel's decision is often difficult with Courts showing deference to expert panels.

Background of the Case

On September 8, 2015, Apotex Inc. ("Apotex") applied for judicial review of the Director General's July 16, 2015 decision (the "Final SLS Decision"), denying Apotex's Abbreviated New Drug Submission ("ANDS") for 100 mg capsules of Apo-Progesterone. The Final SLS Decision was issued after a four-person internal panel of toxicological experts recommended upholding the Minister of Health's decision to issue a notice of non-compliance ("NON") on April 17, 2014 and a notice of non-compliance/withdrawal ("NON-W") on December 29, 2014, citing concerns that the proposed formulation contained "unusually high levels" of Sodium Lauryl Sulfate ("SLS"), a non-medical ingredient used as an excipient.

Federal Court's Response and Implications

Justice Phelan dismissed Apotex's application for judicial review finding there was no reason to interfere with the Minister of Health's decision. The decision raises several implications for stakeholders in the pharmaceutical and biochemical industry.

(a) Limits of Judicial Review

Courts are typically cautious to interfere with decisions made by an expert panel. This Court made several comments with respect to the panel affirming and supporting this deferential approach:

  1. ANDS applicants have a right and legitimate expectation to an independent and impartial panel, but cannot dictate the panel's composition, in this case demanding an external panel. The Director General has the discretion to convene an internal or external panel as long as it is impartial. The Court considered whether the panel was impartial but otherwise made no comment regarding the Director General's discretion to assemble the panel.
  2. The panel should be allowed to update itself on the "state of the art" using publicly available sources.
  3. The panel may comment on the nature and quality of the scientific evidence by referencing regulatory standards and is not required to draw the applicant out on front and centre issues.
  4. Panel members may have prepared notes during the hearing, so long as the ultimate decision is not cast in stone. This means that pharmaceutical companies should be attuned to how their submissions influence the decision-maker's drafted conclusions to determine how preliminary the notes truly are. Some indicators include: whether the notes are merely preliminary thoughts, and whether the panel kept an open mind, accepted the applicant's submissions and considered new information.

This deferential approach is in line with the other, albeit few judicial review decisions regarding NONs and NON-Ws, such as in Apotex Inc. v Canada (Minister of Health) (2009 FC 452), where Justice Phelan upheld the Minister of Health's decision and noted that it was "sufficient that the Minister's opinion or lack of satisfaction [be] rationally and adequately explained." This deference may also be a result of the Minister of Health's important task of ensuring that drugs that are on the market are safe and effective.

What has emerged, then, is a situation in which judicial review has become a tool of last resort and, even then, rarely results in a different decision. As a result, prospective ANDS applicants should consult counsel early and submit a fulsome ANDS in the first instance, as obtaining a favourable result after a request for reconsideration is often challenging.

(b) Evidence Relied On

The Court based its decision partly on the reasoning that Apotex put forward evidence that suffered from numerous shortcomings:

  1. Apotex's claim that the US-FDA approved an Apotex product with higher maximum daily intake of SLS was missing information, did not address the drugs' differing characteristics and did not address the other reasons why the excipient levels were approved.
  2. The evidence regarding toxicology of SLS was of low quality, included a study that the Bureau of Metabolism, Oncology and Reproductive Sciences rejected, was missing important information on the SLS such as tests and evaluations of toxicological endpoints, was sometimes unpublished and did not meet the current regulatory standards or comply with Good Laboratory Practice.

This highlights the importance of presenting comprehensive and persuasive studies to withstand detailed, technical and expert review. Submitting a few studies and stating that another jurisdiction approved a related drug is not, in other words, always sufficient.

(c) Timing

The Court considered Apotex's late application. It reasoned that, while Apotex filed its application late in the honest but mistaken belief that the Director General's communications with Apotex after the Final SLS Decision meant that the Director General would reconsider Apotex's request, the Court could still consider Apotex's application because Apotex had a reasonable explanation for the delay: if it filed for judicial review, any reconsideration would be terminated. As a result, pharmaceutical companies may, depending on the circumstances, still apply for judicial review after the deadline if they have a compelling explanation.

This article was written with the helpful contribution of Patricia Wood (Articling Student).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.